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Polyglutamine (polyQ) diseases are a group of inherited neurodegenerative disorders
caused by the expansion of the cytosine-adenine-guanine (CAG) repeat. This
mutation encodes extended glutamine (Q) tract in the disease protein, resulting
in the alteration of its conformation/physiological role and in the formation
of toxic fragments/aggregates of the protein. This group of heterogeneous
disorders shares common molecular mechanisms, which opens the possibility
to develop a pan therapeutic approach. Vast efforts have been made to
develop strategies to alleviate disease symptoms. Nonetheless, there is still
no therapy that can cure or effectively delay disease progression of any of
these disorders. Mesenchymal stromal cells (MSC) are promising tools for the
treatment of polyQ disorders, promoting protection, tissue regeneration, and/or
modulation of the immune system in animal models. Accordingly, data collected
from clinical trials have so far demonstrated that transplantation of MSC is safe
and delays the progression of some polyQ disorders for some time. However,
to achieve sustained phenotypic amelioration in clinics, several treatments may
be necessary. Therefore, efforts to develop new strategies to improve MSC’s
therapeutic outcomes have been emerging. In this review article, we discuss the
current treatments and strategies used to reduce polyQ symptoms and major
pre-clinical and clinical achievements obtained with MSC transplantation as well
as remaining flaws that need to be overcome. The requirement to cross the
blood-brain-barrier (BBB), together with a short rate of cell engraftment in the
lesioned area and low survival of MSC in a pathophysiological context upon
transplantation may contribute to the transient therapeutic effects. We also review
methods like pre-conditioning or genetic engineering of MSC that can be used
to increase MSC survival in vivo, cellular-free approaches—i.e., MSC-conditioned
medium (CM) or MSC-derived extracellular vesicles (EVs) as a way of possibly
replacing the use of MSC and methods required to standardize the potential of
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MSC/MSC-derived products. These are fundamental questions that need to be
addressed to obtain maximum MSC performance in polyQ diseases and therefore
increase clinical benefits.
Keywords: mesenchymal stromal cells, polyglutamine disorders, neurodegenerative disorders, cell therapy,
extracellular vesicles, secretome
INTRODUCTION
Polyglutamine (polyQ) diseases are a group of nine inherited
neurodegenerative disorders including dentatorubral
pallidoluysian atrophy, spinal bulbar muscular atrophy (SBMA),
Huntington’s disease (HD), and spinocerebellar ataxias (SCAs)
type 1, 2, 3, 6, 7 and 17. All of them are autosomal dominant,
apart from SBMA, which is X-linked (Orr and Zoghbi, 2007).
PolyQ disorders are associated with the unstable expansion of
the cytosine-adenine-guanine (CAG) trinucleotide repeat in the
respective causative gene. Such mutation encodes for extended
glutamine (Q) tract, which occurs in different proteins according
to the disorder, thus having unrelated functions and distinct
cellular and subcellular locations. Nonetheless, all polyQ diseases
share common features suggesting that the polyQ stretch directly
contributes to the toxic properties of these proteins through a
‘‘toxic gain of function.’’
Although these disorders express distinct symptoms, all of
them greatly impact a patient’s quality of life by leading to both
physical and psychological complications. Some of the shared
common features include: onset typically during midlife; the
inverse correlation between the number of repeats and the age
of onset; degeneration of specific neuronal subpopulations that
slowly progress over 10–20 years after the onset, culminating
in premature death (Maciel et al., 1995; Ranum et al., 1995;
Dürr et al., 1996; Zoghbi and Orr, 2000). The cerebellum,
basal ganglia, brainstem nuclei, and spinal motor nuclei are
some of the regions of the nervous system that are transversely
affected in polyQ diseases (Zoghbi and Orr, 2000; Ross et al.,
2003). The neuropathological alterations are the result of cellular
changes such as accumulation of polyQ proteins in the cytoplasm
and nucleus, the formation of inclusions, disturbance of the
quality control systems of the cell, mitochondrial dysfunction,
axonal transport disruption, synaptic activity decline, and
neuroinflammation (Shao and Diamond, 2007; Havel et al.,
2009). Additionally, the generation of toxic fragments resulting
from the proteolytic cleavage has also been described in a few
polyQs. The existence of common pathological mechanisms
opens windows for the design of possible common therapies. In
that sense, cell therapies and cellular-derived treatments are good
candidates to be used for that purpose.
Currently, besides palliative care, treatments for polyQ
disorders are only able to suppress or reduce specific symptoms.
Levodopa or a dopamine agonist have been successful in
cases displaying parkinsonian features, with dystonia and
bradykinesia also being reduced through this approach (Tuite
et al., 1995; Paulson, 2007). Furthermore, gait symptoms plus
dysarthria can be improved by occupational and physical
therapy, and dysphagia might be ameliorated by implementing
strategies on what and how patients eat to avoid complications
(Paulson, 2007). On the other hand, since pre-symptomatic
testing already exists, medical and ethical guidance regarding
treatment and parenthood counseling can be given, not only
to post-symptomatic patients but also to pre-symptomatic
individuals (Sequeiros et al., 1998; Drüsedau et al., 2004;
Bettencourt and Lima, 2011; Schuler-Faccini et al., 2014).
Despite the efforts that have been made to develop effective
therapies, there is still no strategies that can prevent, cure, or
delay the progression of polyQ disorders.
Promising molecular and cellular therapies have been
investigated in the last decades. Regarding gene therapy, the most
frequently usedmethod consists of silencing the defective protein
resulting from the CAG expansion in a given gene (depending
on the polyQ), mostly using RNA interference. However, there
are challenges regarding delivery to the central nervous system
and the risk of off-target effects. Significant progress has been
made regarding this approach and such strategies will probably
be implemented soon. Still, since the genetic defects differ from
disorder to disorder, the strategy will require adaptations for
each disease. As this subject is not the main focus of this review,
we will not discuss it in detail, but this subject is reviewed in
Matos et al. (2018).
Cellular therapies, on the other hand, may exert a pan effect
on the common defective mechanisms that polyQ disorders
share, as described above. For that, neural precursor and neural
stem cells, embryonic stem cells, induced pluripotent stem cells,
andmesenchymal stem cells (MSC) can be envisioned. Naturally,
each source of the referred stem cells has its advantages,
drawbacks, and success upon usage in polyQ diseases, as
summarized elsewhere (Mendonça et al., 2018). Presently, MSC
is not the first choice for cellular therapies in neurodegenerative
conditions. Nonetheless, they are undoubtedly the safest kind
among the different stem cells that can be used for therapeutic
purposes since they are adult cells, and thus, not prone to develop
tumors in a stable organism. Therefore, they have been widely
used in studies of neurodegenerative disorders, including polyQs.
However, despite some promising results, some aspects need
to be improved to amplify MSCs healing effects and achieve
translational significance. These concerns will be discussed in the
present review article.
MESENCHYMAL STROMAL CELLS (MSC):
PROMISING TOOLS FOR THE
TREATMENT OF PolyQ DISORDERS?
Mesenchymal stromal cells (MSC) are adult multipotent
progenitor cells capable of giving rise to tissues from the
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mesenchymal lineage. They were described in the 70’s decade
by Friedenstein et al. (1970, 1974) and since the discovery
of their multipotency in 1997 (Prockop, 1997), their use in
cellular therapies for neurodegenerative disorders suffered
a steadfast evolution, due to the high potential/low-risk
balance (Figure 1).
In neuronal context, their role was initially thought to be
associated with the replacement of aged and damaged cells
(Wakitani et al., 1995; Pittenger et al., 1999) but, currently,
there is consensus that this is not their principal mode of
action. Cell fusion was also described to occur by some authors.
Of note, this mechanism was described in a SCA1 mouse
model, where Purkinje cells (PCs) of the host animals fused
with MSC (Huda et al., 2016). However, this mechanism
is rare in the literature and does not appear to account
significantly for MSC’s overall outcomes. So MSC’s main effects
are probably mainly mediated by influencing neighboring
cells, through secretion of bioactive factors, or by inducing
secretion of these factors in host cells, thus being able to
modulate the immune system and to promote tissue repair
(Gao et al., 2001; Tremain et al., 2001). The establishment
of strong communication through chemical signals between
MSC and surrounding cells, which can be either other MSC,
neurons, astrocytes, or glia, is thought to be the anchor for
MSC’s therapeutic capabilities. Indeed, MSC can respond
to stress ‘‘signals’’ of the nearby cell by modulating their
molecular pathways towards the production of specific factors,
which can support these cells under stress (Millard and Fisk,
2013). As an example, a mechanism called ‘‘bio bridge’’ in
which MSC seem to form a stream of extracellular matrix
(bridge) between the lesion site and neurogenic niches was
described for some neurological contexts such as traumatic
brain injury and stroke, and could occur in other neurological
disorders (Tajiri et al., 2013; Sullivan et al., 2015). This bridge is
concomitant with higher expression levels of metalloproteinases
(MMP) such as MMP9, leading to better communication
between MSC and endogenous neuronal precursors and
increment in neurogenesis post-lesion. Precursors cells from
neurogenic niches then reach the brain-lesioned tissue, replacing
injured cells. For all these mechanisms, there is evidence
of bidirectional communication exerted through bioactive
soluble molecules [neurotrophins, cytokines, chemokines,
microRNAs (miRNAs), etc.], extracellular vesicles (EVs; that
can contain proteins, RNAs, or even DNA) or by direct contact
(e.g., via tunneling nanotubes or throughmechanotransduction).
Therefore, depending on the defects in the host damaged
tissue, MSC may: (1) modulate inflammatory processes;
(2) reduce oxidative stress, either by inducing survival
pathways or by the direct transfer of healthy mitochondria
to the host cells (via nanotubes); (3) favor neurogenesis
by the secretion of neurotrophins and by the formation of
‘‘bio bridges’’; (4) induce gliogenesis and remyelination; and
(5) increase axonal survival and plasticity, thus inducing
synaptogenesis (Paul and Anisimov, 2013; Figure 2). These
exquisite cross-talks lead to a wide evaluation of MSC
for the therapy of neurological diseases in preclinical and
clinical models.
From Alzheimer’s (AD) to Parkinson’s (PD) or HD, the
encouraging effects of MSC in a few pre-clinical studies
prompted clinicians to perform preliminary clinical trials to
evaluate their safety and/or effectiveness. However, this process
started before fundamental issues were properly addressed
at the pre-clinical level, which led to some disappointing
results relative to the ones expected. Due to the initial lack
of information, strategies did not contemplate solutions for
problems such as the challenge of surpassing the blood-
brain barrier (BBB), the low rate of cells engraftment in the
lesioned tissue, the low survival of MSC, or the unidentified
mechanisms involved in MSC’s positive effects. Finally, the
standardization of MSC source of cells or even of methods
capable of evaluating their potential, are imperative to make
translation possible.
The investigation in this field is therefore currently aiming
at resolving these difficulties and giving answers to the urgent
need of efficacious therapies for neurodegenerative disorders for
which therapeutic tools are presently scarce.
FIGURE 1 | Timeline of mesenchymal stromal cells (MSC)’s history and their use in neurodegenerative disorders (Friedenstein et al., 1970; Owen and Friedenstein,
1988; Caplan, 1991; Prockop, 1997; Chopp et al., 2000; Mazzini et al., 2003; Bonafede et al., 2016).
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FIGURE 2 | MSC’s paracrine mechanism(s) in neuronal cells.
This review gives an overview of this subject with a particular
focus on polyQ disorders, which besidesHD, are scarcely referred
to in the literature.
Pre-clinical Studies Assessing MSC’s
Therapeutic Potential in PolyQs
Several pre-clinical studies have investigated the therapeutic
efficiency of MSC isolated from different sources, including
bone marrow (BM-MSC), adipose tissue (AD-MSC), and
umbilical cord (UC-MSC), in rodent models of HD. HD is the
polyQ disease with the highest prevalence worldwide affecting
about 1 in 7,500 individuals (Evans et al., 2013; Fisher and
Hayden, 2014). HD causes brain atrophy in several regions
such as the striatum, thalamus, cerebellum, brain stem, and
cortex (Harper et al., 2005; Hassel et al., 2008; Labbadia and
Morimoto, 2013; Chao et al., 2017) leading to progressive
motor dysfunction and incoordination, cognitive impairment
and psychiatric symptoms.
Over the last decade, it has been demonstrated that MSC
can relieve phenotype and neuropathology of HD in both
transgenic (Lee et al., 2009; Im et al., 2010; Snyder et al.,
2010; Lin et al., 2011; Yu-Taeger et al., 2019) and chemically-
induced models (Lee et al., 2009; Edalatmanesh et al., 2011;
Rossignol et al., 2011, 2015; Hosseini et al., 2015; Ebrahimi
et al., 2018). These studies show that animals treated with
MSC displayed improved behavioral performance, cognitive
functions, and, in the excitotoxic Quinolinic Acid (QA)-induced
HD rats, reduction of apomorphine-induced rotation. Hosseini
et al. (2015) also showed that MSC was able to reduce anxiety
levels in treated QA-induced HD rats. Also, the administration
of MSC was able to increase the survival of the R6/2 mouse
model (Lee et al., 2009; Lin et al., 2011; Yu-Taeger et al., 2019).
Importantly, one of these studies pointed out the importance
of well-dosing the number of MSC administered. The authors
compared two different doses of MSC (2 × 105 and 4 × 105)
and surprisingly only the group treated with the lowest dose
presented motor improvements (Rossignol et al., 2011). The
authors concluded that a high number of MSC may cause tissue
damage to striatal architecture.
Regarding neuropathological improvement, MSC preserved
the volume of the striatum, induced neurogenesis, and
differentiation of the host endogenous neural stem cells, and
reduced neuronal death (Snyder et al., 2010). Lin et al.
(2011) saw a decrease in the levels of Bax and caspase-3
as well as an up-regulation in the expression of Erk1/2,
which suggests that MSC can inhibit apoptosis and promote
neuronal survival. Furthermore, this study points out the strong
capability of MSC for recruiting microglia, neuroblasts, and
bone marrow-derived cells to the lesion site which helps tissue
regeneration (Lin et al., 2011). MSC administration has also
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FIGURE 3 | Schematic representation of exosome biogenesis and molecular composition. Exosomes have an endocytic origin and are released to the extracellular
milieu upon the fusion of MVB with the plasma membrane. Other MVB may fuse with lysosomes leading to their degradation. Overall, exosomes surface markers,
cytoskeleton, and cellular metabolism proteins are common to those of the cell of origin. Plus, exosomes also include signaling proteins, DNA, several types of RNA,
and lipids. Abbreviations: ESCRT, Endosomal Sorting Complex Required for Transport; MVB, Multivesicular bodies; mRNA, messenger RNA, miRNA, microRNA.
led to the reduction of the number of huntingtin aggregates
(Lee et al., 2009).
Notably, Yu-Taeger et al. (2019) showed that MSC could
ameliorate disruptions in the dopaminergic signaling cascade,
increasing the expression of DARPP-32 and tyrosine hydroxylase
in the striatum, known to be reduced in R6/2 HD mice (Bibb
et al., 2000). This study also evidenced the immunomodulatory
potential of MSC as treated mice restored the expression of Iba1,
and microglia morphology in the striatum, plus inducing the
downregulation of several inflammatory modulators (Yu-Taeger
et al., 2019).
The feasibility of performing autologous transplants in HD
has also been assessed. Researchers compared the efficacy of
AD-MSC isolated from the subcutaneous adipose tissue of
an HD patient and a healthy donor in the treatment of
YAC128 transgenic mice, a long-lived HD model (Im et al.,
2010). Even though both kinds of cells expressed the same
cell surface markers and showed a similar secretory potential
in terms of neurotrophic factors, normal AD-MSC could
reduce striatal atrophy when they were transplanted into 8
month-old YAC128 mice, whereas HD AD-MSC failed to
promote such benefits. Nonetheless, the injection of cells in
this time-window did not produce improvements in any of
the treated groups regarding rotarod performance or body
weight. On the contrary, when transplanting normal AD-MSC
at 12 months of age, there were significant improvements in
motor performance. These results show that AD-MSC could
modify the course of HD in long-lived mice, though their
effect is dependent on the donor condition and time window
of delivery.
More recently, two studies assessing how the number of
passages of MSC in ex vivo cultures can affect their therapeutic
effects were performed in R6/2 transgenic mice (Fink et al., 2013;
Rossignol et al., 2015). In the first study, BM-MSC isolated from
mice were grown for a low (3–8) or high (40–50) number of
passages, and no neuronal or glial differentiation was observed.
The striatum of R6/2 mice transplanted with BM-MSC at higher
passage showed increased metabolic activity compared with
non-treated R6/2 mice and significantly-improved behavioral
sparing compared to either untreated R6/2 mice or R6/2 mice
receiving low-passage BM-MSC. Thus, the passage number of
BM-MSC expansion could alter their efficacy.
In the second study, they compared the therapeutic
potential of low- (3–8) and high-passage (40–50) UC-MSC
in the R6/2 transgenic HD mouse model (Fink et al., 2013).
Interestingly, high-passage UC-MSC showed a higher survival
rate in vivo, but contrary to the previous study, both transplanted
groups showed increased metabolic activity and reduced brain
damage in the striatal area. Moreover, no major differences
were observed in the motor and non-motor behavioral tests
compared with non-treated HD mice. In contrast, Ebrahimi
and collaborators showed that the administration of UC-MSC
at a low passage in 3-NP lesioned rat models led to significant
improvement of motor performance and muscle activity. Plus,
they also observed neuropathological ameliorations as UC-MSC
were able to decrease gliosis and increase both the striatal volume
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and dendritic length of striatal cells (Ebrahimi et al., 2018). So,
as a conclusion, the time of MSC expansion and concomitant
number of passages is an important parameter and should be
further and carefully addressed in future assessments.
The relief of phenotypical and neuropathological defects
in HD models has been associated with MSC trophic effect.
Several studies reported that MSC transplantation increased
the expression of both messenger RNA (mRNA) and protein
levels of brain-derived neurotrophic factor (BDNF) in the
striatum (Snyder et al., 2010). Additionally, Snyder et al.
(2010) reported that BM-MSC transplantation led to increased
expression of the neurotrophic factors fibroblast growth factor
(FGF), ciliary neurotrophic factor (CNTF), vascular endothelial
growth factor (VEGF), and nerve growth factor (NGF).
Over-expression of collagen type-I and fibronectin in the
striatum of MSC-treated animals has also been observed which
contributes to the stabilization of the extracellular matrix,
helping tissue regeneration (Rossignol et al., 2011).
Regarding other polyQ disorders, few preclinical studies
have been performed in mouse models of SCA1, SCA2, and
SCA3. Despite the causative mutation being located in different
genes, an expansion of the CAGs in ATXN1, ATXN2, and
ATXN3 (also known asMJD1), respectively, many symptoms and
major mechanisms involved in disease progression are similar
among SCAs (Paulson, 2009; Klockgether et al., 2019; Sullivan
et al., 2019). Over time, patients develop motor incoordination
as the main progressive clinical feature, along with tremors,
muscle rigidity, dysarthria, dysphagia, peripheral neuropathy,
oculomotor problems (such as double vision, nystagmus or
ophthalmoplegia), and parkinsonism in some cases (Paulson,
2009). Cognitive impairments have also been pointed out
to occur.
MSC’s effect has shown to be equally promising in these
groups of polyQs, demonstrating that they can alleviate motor
function deterioration in SCAs. A pre-symptomatic study was
performed in a transgenic mouse model of SCA-1 (SCA1-Tg
mice). Intrathecal (IT) injection of an MSC line (KUM10) in
SCA1-Tgmice led to neuropathological improvements.MSCwas
shown to migrate towards the cerebellum and mitigate neuronal
disorganization. The cerebellum of these SCA1 transgenic mice
had ectopically-located PCs bodies that resulted in a multilayer
of PC, and mice showed atrophy of the cerebellar molecular layer
(ML). In the referred study, MSC-treated mice displayed a single
layer of PC and the ML was thicker than that of the untreated
mice. Motor function assessed by the rotarod test was also shown
to be improved in treated animals (Matsuura et al., 2014).
Additionally, MSC showed to mitigate motor functions
deterioration in a SCA2 transgenic mouse model (Chang et al.,
2011). The study compared the efficacy of repeated intravenous
(IV) or intracranial (IC) injections of human BM-MSC and
concluded that IV infusions effectively delayed diseases’ onset
and improved motor performance by rescuing cerebellar PC,
whereas IC injections failed to improvemotor skills. In this study,
more grafted BM-MSC were found in the IV transplantation
group, located in the cerebellum and cerebral cortex (CC).
The authors explained the higher success of IV delivered
BM-MSC due to the extravasation capacity as cells migrated
from intracranial vessels through white matter (WM) into several
regions of the cerebellum.
Our group has recently demonstrated that mouse BM-MSC
transplantation can ameliorate both phenotypical and
neuropathological MJD symptoms in Machado–Joseph
disease (MJD)/SCA3 (Oliveira Miranda et al., 2018). In
agreement with the previous study, our investigation showed
that the administration of several consecutive IV injections of
BM-MSC sustainably ameliorated motor impairments, when
delivered post-symptomatically. Using intracerebroventricular
administration (ICV), a single injection could only alleviate MJD
symptoms transiently in the same Tg-ATXN3-69Q transgenic
mouse model of MJD (Torashima et al., 2008). This suggests
that repeated treatment through the IV route led to better
outcomes. Notably, our results were in line with Li et al. (2018)
findings, which showed that repeated systemic treatment of
pre-symptomatic transgenic homozygous MJD mice [SCA3-
YAC-84Q; (Cemal et al., 2002)] with human UC-MSC was able
to alleviate motor impairments and neuropathology of MJD.
These findings were corroborated with low survival and poor
engraftment in host tissues, which represent a common problem
in these therapies. In our study, we demonstrated that after
ICV transplantation, despite cells surviving up to 8 weeks after
transplantation, the SPION-labeled MSC signal was drastically
reduced from 1 to 8 weeks in vivo. Moreover, BM-MSC delivered
IV was detected in the brain of mice 30 min after transplantation,
but completely disappeared from circulation before completion
of 7 days (Oliveira Miranda et al., 2018). Similarly, other studies
in HD animal models also observed that MSC remained only for
a short time in the lesion site (Snyder et al., 2010), or in other
cases, although the authors could detect cells in the brain, only a
small percentage of the implanted cells could survive (Lee et al.,
2009; Im et al., 2010; Snyder et al., 2010; Lin et al., 2011; Yu-
Taeger et al., 2019). A concise review of these studies is given in
(Table 1).
Interestingly, these studies in SCAs also relate the action of
MSC to neuronal survival/activity pathways, which is following
the previous studies performed in HD rodent models. In the
study of Li et al. (2018), the neuroprotective action of MSC
was linked with the upregulation of the insulin-like growth
factor 1/heat shock protein 70 (IGF-1/HSP70) pathway. In
our study, we demonstrated that MSC protected GABAergic
and Glutamatergic neurons, as by proton magnetic resonance
spectroscopy (1H-MRS) we detected an increased expression of
Gaba and the complex Glutamine-Glutamate upon a treatment,
along with increased levels of mRNA for the receptors
Gabrb2 and Grm1 in the cerebellum, denoting a higher synaptic
activity (Oliveira Miranda et al., 2018).
In conclusion, despite the general agreement on the fact
that MSC promotes beneficial outcomes in polyQ diseases, the
different severity grades of the rodent models used as well as
the ability to simulate human diseases make the interpretation
of the potency scale of the treatments difficult. The development
of models that better recapitulate polyQ diseases neuropathology
in humans would be essential. Thus, knock-in models of larger
mammals like the HD CRISPR-Cas9 knock-in pig model that
shows strong neurodegeneration patterns (Yan et al., 2018) could












TABLE 1 | Sum up of the survival, grafting, and integration of mesenchymal stromal cells (MSC) in pre-clinical studies in animal models of polyglutamine (polyQ) disorders.
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List of abbreviations: HD, Huntington’s disease; QA, quinolinic acid; BM-MSC, Bone marrow-derived mesenchymal stromal cells; AD-MSC, adipose tissue-derived mesenchymal stromal cells; BDNF, Brain-derived neurotrophic factor;
GABA, gamma-aminobutyric acid; GAD, glutamic acid decarboxylase; YAC, yeast artificial chromosome; ND, not determined; GFAP, glial fibrillary acidic protein; NeuN, neuronal nuclei; DARP-32, dopamine- and cAMP-regulated neuronal
phosphoprotein; F4/80, major macrophage marker; UC-MSC, umbilical cord-derived mesenchymal stromal cells; 3-NP, 3-nitropropionic acid; SCA1, Spinocerebellar ataxia type-1; SCA2, Spinocerebellar ataxia type-2; IV, Intravenous
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be an important contribution to the field to validate findings
achieved with rodent models and test a possible replacement of
degenerated neurons promoted by MSC.
Furthermore, different cell sources, heterogeneous methods
of isolation, discrepancies in MSC origins (i.e., from
healthy/disease tissues) and characteristics (cell passage
number, conditions used during cell growth) have been
used throughout the studies, which makes it difficult to reach
a correct comprehension and make assertive conclusions with
enough confidence to implement these therapies in the clinics.
Clinical Studies in PolyQ Patients:
Achievements and Flaws
Despite the extensive number of unanswered issues from the
pre-clinical assessments herein referred, the promising results
obtained from research on the use of MSC in polyQ soon
led to the investigation of their therapeutic application in
clinical studies. The clinical trials, mostly phase I/II, aiming
at testing the safety and effectiveness of MSC in the treatment
of polyQ disorders (completed and ongoing clinical trials—
ClinicalTrials.gov Identifiers: NCT02728115, NCT03252535,
NCT04219241, NCT03378414 for HD and NCT01360164,
NCT01489267, NCT01649687, NCT02540655 for other
polyQs/SCAs) are summarized in Table 2.
Data collected from four of these clinical trials have
demonstrated that the therapeutic application of MSC is safe,
does not produce severe side effects and might delay the
progression of disease symptoms (Dongmei et al., 2011; Jin
et al., 2013; Miao et al., 2015; Tsai et al., 2017). In one
of these studies, fourteen patients diagnosed with SCA and
ten with multiple system atrophy-cerebellar type C (MSA-C)
were treated weekly with IT injections of UC-MSC at a dose
of 1 × 106/kg during four weeks (except for three patients
who received two courses of treatment, all the other patients
received only one course). Furthermore, the neuronal function
and quality of daily life were assessed through the International
Cooperative Ataxia Rating Scale (ICARS) and Activity of Daily
Living Scale (ADL). Improvements in ICARS and ADL scores
were observed after 1 month of treatment (Dongmei et al.,
2011). In another study, Jin et al. (2013) demonstrated that
MSC treatment could alleviate SCA symptoms for at least half
a year. In this study, 16 patients diagnosed with SCA1, 2 or
3, received IV or IT injections of UC-MSC (first treatment:
4 × 107 UC-MSC were infused iv.; following three treatments:
2 × 107 UC-MSC were infused IV and simultaneously 2 × 107
UC-MSC were infused by IT administration; all patients received
only one-course treatment). Results showed that most patients
obtained improved scores on the Berg Balance Scale (BBS),
which evaluates patients’ balance, and ICARS at 3 and 6 months
after treatment (Jin et al., 2013). A different clinical trial using
UC-MSC was performed to evaluate the technical difficulties
underlying IT UC-MSC injection via lumbar puncture and assess
the effects of the cell in different neurodegenerative disorders,
including eight SCA patients (Miao et al., 2015). The UC-MSC
was injected 4–6 times between the L4 and L5 interspace
within 5–7 days (single course of treatment). All patients were
followed-up for more than 1 year for clinical status. Three of
the eight patients showed motor function improvement after
treatment. Recently, Tsai et al. (2017) intravenously administered
(5–7 × 107) allogeneic MSC derived from the adipose tissue
(AD-MSC, single injection) into six patients with MJD and one
with MSA, who showed a slight trend of improvement and
stabilization of the disease according to the Scale for Assessment
and Rating of Ataxia (SARA) and the sensory organization
testing (SOT).
Importantly, no major side effects were reported, besides
dizziness, headache, back pain in case of IT injections, or fever
(Dongmei et al., 2011; Jin et al., 2013; Miao et al., 2015; Tsai et al.,
2017). Consistently with these results, no adverse effects were
reported so far in any of the pre-clinical studies. Moreover, in
our study, we assessed for the levels of hepatic aminotransferases,
which were not increased when compared to non-treated or
WT mice, denoting the absence of liver toxicity in mice treated
repeatedly with MSC (Oliveira Miranda et al., 2018).
Altogether, the studies reinforce the safety and tolerability
of MSC. Furthermore, they demonstrate that treatment with
allogenic UC-MSC may delay disease progression, improving
motor performance, and patients’ quality of life without severe
adverse reactions. However, the regression of some patients
to the status before the treatment was reported (Dongmei
et al., 2011; Jin et al., 2013; Miao et al., 2015; Tsai et al.,
2017; summarized in Table 2). This was also following the
need for performing several treatments suggested by some of
the pre-clinical studies (Chang et al., 2011; Li et al., 2018;
Oliveira Miranda et al., 2018). Nonetheless, in the clinical
context, periodic MSC injections may not be feasible as they
could lead to unwanted side effects. Indeed, some studies
highlighted the long-term risk that could emerge from the
repeated therapeutic transplantation of these cells, namely
maldifferentiation, immunosuppression (increasing the risk of
opportunistic infections), liver and lung accumulation, and
malignant tumor growth promotion in patients with pre-existing
malignancy (Sundin et al., 2006; Dierks et al., 2007; Kunter
et al., 2007; Ning et al., 2008). On the other hand, as previously
discussed, the local administration of MSC may cause brain
damage if administered above a certain number (Rossignol et al.,
2011). Therefore, it would be important to further clarify the
mechanism involved in MSC therapeutic effects, uncovering
new potential treatments that do not require the infusion
of cells.
On the other hand, these clinical trials often mix patients
with different conditions/stages of the disease and frequently
include all disorders when reporting results, making reports
not as informative as desired. Future clinical studies should
focus not only on the feasibility of repeated treatments for
sustained benefits but also on the appropriate timing, dosage
and best method of injection to be used, while also performing
longer follow-ups of all patients to evaluate treatment efficacy
and safety, and with placebo-controls being used. For that
purpose, established cohorts, well-defined and characterized
must be performed so that clinical studies can be well-designed
and as instructive as possible. An example of such a cohort
has been implemented by the European Consortium ESMI
(‘‘European Spinocerebellar Ataxia Type 3/Machado-Joseph












TABLE 2 | Concise information on the outcomes obtained from clinical trials performed with MSCs in patients with PolyQ diseases.
Trial identification Disease Type of MSC Route of administration Outcomes
Dongmei et al. (2011)
SCA and MSA-C UC-MSC IT ICARS and ADL (Katona et al. (2008)) scores significantly decreased 1 month after
treatment. Unstable walking and standing, slow movement, fine motor disorders
of the upper limbs and writing difficulties, and dysarthria were greatly improved
except for 1 patient, who had no response.
Ten cases (42%) remained stable for half a year or longer, while 14 cases (58%)






UC-MSC IV and IT After 1 year of treatment: 44% of the patients exhibited improved Berg Balance
Scale (BBS) over baseline, and only 31% of the patients suffered from disease
aggravation; 63% of the patients exhibited improved ICARS over baseline, and
only 25% of the patients suffered from disease exacerbation.




UC-MSC IT Patients were followed-up for more than 1 year. No significant side effects were
reported. Three of the 8 patients with SCAs (37.5%) showed motor function
improvement 1 year after the treatments.
NCT01489267 SCA1 UC-MSC IT Unknown
NCT01649687 Tsai
et al. (2017)
SCA3 or MSA-C AD-MSC IV Patients were monitored for 1 year with no reported adverse events. They showed
an initial trend toward brief improvement, followed by a slight stabilization and a
progression of the disease in later stages.
At 6 months follow-up, SARA scores were improved in 2 (33.3%), unaltered in 2
(33.3%), and worsened in 2 (33.3%) patients as compared with the baseline. At
1-year follow-up, SARA scores were improved in 1 (16.6%), unaltered in 3 (50%),
and worsened in 2 (33.3%) patients as compared with the baseline.
NCT02540655 Cerebellar Ataxias AD-MSC
(Stemchymalr)
IV Unknown.
NCT02728115 HD Cellavita* IV Active, not recruiting
NCT03252535 HD Cellavita IV Active, not recruiting




List of abbreviations: SCA, Spinocerebellar ataxia; MSA-C, and multiple system atrophy-cerebellar types; SCA1, Spinocerebellar ataxia type-1; SCA2, Spinocerebellar ataxia type-2; SCA3, Spinocerebellar ataxia type-3 or Machado-
Joseph disease; SCA6, Spinocerebellar ataxia type-6; UC-MSC, umbilical cord-derived mesenchymal stromal cells; AD-MSC, adipose tissue-derived mesenchymal stromal cells; IT, Intrathecal injection; IV, Intravenous injections; ICARS,
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Disease Initiative,’’ Joint Programme on Neurodegenerative
disorders), which put together eight European cohorts that
over the last 4 years integrated all the existing data in
a common database to allow for standardized and quality-
controlled protocols in the forthcoming studies.
Major Questions to be Addressed to
Increase Clinical Benefits
From the clinical studies referred so far, we can conclude that
the major weakness of the cellular therapies using MSC (or
another adult/progenitor stem cell source) is that their effect
is not prolonged throughout time. However, the cause of these
transitory effects of MSC in vivo remains elusive. In our study,
we could determine that MSC survival was limited in time after
administration, which is consistent with other pre-clinical studies
(as shown in Table 1). This may result from the inhospitable
environment they face—the high oxidative stress of the damaged
tissue, together with the low glucose availability—that leads MSC
to choose an anerobic metabolic pathway, forcing cells to rapidly
undergo apoptosis (Moya et al., 2018). Methods for increasing
MSC fitness are described in the following section.
Another important question is whether MSC can effectively
pass through the BBB upon intravenous injection. Several
pre-clinical studies reported the finding of MSC in the central
nervous system, including ours, as referred in Table 1. However,
whether MSC crosses this barrier by mechanisms that are
similar to leukocytes such as transmigration (Chamberlain et al.,
2007), or whether this barrier needs to be impaired to let MSC
pass-through remains undetermined. BBB leakage was already
described for HD (Drouin-Ouellet et al., 2015). Due to the strong
presence of inflammatory mechanisms in polyQ disorders, it can
be speculated that this is also the case for the remaining polyQs.
In accordance, we recently reported evidence that the BBB is
damaged inMJD (Lobo et al., 2020). Still, there are no indications
that the BBB opening is mandatory for MSC to reach the
brain parenchyma. Studies accessing MSC biodistribution inside
the nervous system in non-neurodegenerative rodents (wild
type animals), should be performed to answer this intriguing
question. In case MSC cannot cross the BBB when it is fully
preserved, then other strategies should be explored such as the
expression of specific receptors on the MSC surface that would
allow their passage, or consider the use of MSC products (either
naïve or engineered) that can effectively reach brain cells.
Finally, the prophylactic administration of this cellular
treatment is also an important issue to be discussed. Since
these disorders are monogenic and can be passed to the
offspring, the patients can choose to know whether they carry the
disease mutation before the manifestation of disease symptoms.
Therefore, successful treatment could be implemented in
pre-symptomatic patients. Accordingly, there is evidence that
this would favor a later appearance of symptoms (Snyder et al.,
2010; Li et al., 2018), supporting such early intervention as
a feasible clinical approach for polyQs patients in the future.
Nonetheless, Im and collaborators showed that MSC only
modified the course of the disease when administered after its
phenotypic expression in long-lived HD transgenic mice (Im
et al., 2010). Therefore, the time window of delivery should be
further investigated.
Overall, both pre-clinical and clinical studies show the
therapeutic relevance of MSC for polyQ but also highlight the
need to design better clinical approaches and more adjusted
to the real biology and behavior of cells upon transplantation.
Possible solutions are discussed in the following sections.
METHODS TO INCREASE MSC’s
EFFICACY IN VIVO
Strategies to overcome some of these shortcomings and improve
MSC’s efficiency have been explored and will be described next,
such as pre-conditioning of cells, the use of adjuvant factors, or
the genetic enhancement of MSC. A concise review of that is
given in Table 3.
Pre-conditioning of MSC
Knowing that the secretion of soluble and insoluble factors
is an adaptive mechanism, which allows MSC to regulate
intracellular stress and influence their surroundings, researchers
have investigated whether the pre-conditioning of MSC
could improve their therapeutic abilities. Pre-conditioning
is nothing more than manipulating cells, so they perform
a specific function or undergo a desirable differentiation
pathway. Some studies showed that pre-conditioning of MSC
using hypoxia, different culture conditions, biomolecules
(cytokines and growth factors), or pharmacological compounds,
may lead to greater MSC survival in vivo and enhanced
regenerative and immunomodulatory effects (Ferreira et al.,
2018; Noronha et al., 2019).
Pre-conditioning: Hypoxia
Oxygen tension under standard cell culture conditions (21%)
is much higher than physiological oxygen tension in tissues,
which can vary from 1% to 12% depending on vascularization
and metabolic activity (Das et al., 2010). Notably, when we
speak of hypoxia in the context of cell culture, usually it means
that oxygen availability ranges from 0 to 10% to better mimic
physiological conditions. MSC is usually found in tissues with
low oxygen tension (1% to 7%), is naturally able to endure in
in vivo hypoxic environments (Deschepper et al., 2011).
When cultured under hypoxic conditions, MSC increases
their fitness to adapt to adverse circumstances which will make
them better prepared to face inhospitable environments. Indeed,
under hypoxia MSC changes their metabolism, increasing their
glucose consumption, decreasing the production of oxygen
species, and shortening telomeres (Das et al., 2010). In these
conditions, MSC presents a greater proliferation rate and
increased secretion of soluble factors without changing their
multipotency, which improves MSC capacity to survive in
damaged tissues upon transplantation (Das et al., 2010; Bader
et al., 2015; Lee et al., 2017). Accordingly, Lee et al. (2017)
showed that culturing MSC in hypoxic conditions leads to
the up-regulation of Hypoxia-inducible factor (HIF)-α, which
induces survival and proliferation rate.












TABLE 3 | Summary of results using modified-MSCs in PolyQ diseases in comparison to naive cells—evidence from pre-clinical studies.





























4.2 × 105 Bilateral
delivered at the
lesion site
On the day of
QA induction
NTF+ MSC led to less striatal
volume loss and decreased










with Lithium and VPA






cells survived longer in vivo
(60% more at 9 weeks after
transplants), led to behavioral
improvements, and reduced









1 × 106 IV 1 h before 3-NP
injections
Combined treatment decreased
weight loss, and mortality rate





Dey et al. (2010) YAC
128 transgenic
mice










Both MSC-BDNF or MSC-NGF
treated mice showed improved
rotarod performances with
MSC-BDNF having a greater



















Only MSC-BDNF reduced mice
anxiety levels; MSC-BDNF had


















increased mice lifespan to a
greater extent
List of abbreviations: HD, Huntington’s disease; QA, quinolinic acid; VPA, valproic acid; AD-MSC, adipose tissue-derived mesenchymal stromal cells; BM-MSC, Bone marrow-derived mesenchymal stromal; LER, lercanidipine; BDNF,
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Hence, UC-MSC pre-conditioned with hypoxia
(MSC-h) showed to have neuroprotective, anti-apoptotic, and
anti-inflammatory actions in a rat model of spinal cord injury.
When compared with MSC cultured under standard conditions,
MSC-h exhibited increased expression of neuroprotective
trophic factors, such as hepatocyte growth factor (HGF), BDNF,
and VEGF. Rats transplanted with MSC-h into the spinal cord
immediately after lesion induction showed increased axonal
preservation, even higher as compared to MSC not submitted
to hypoxia. MSC-h also reduced the number of caspase-3
(apoptotic marker) positive cells, microglia, and macrophage
infiltration (Zhilai et al., 2016).
Furthermore, Wang J. W. et al. (2017) demonstrated
that hypoxia pre-conditioning enhanced the migration and
integration of MSC upon transplantation into a rat model of
cerebral ischemia, induced by cardiac arrest. These actions were
linked with the activation of PI3K/AKT pathways and increased
expression of HIF-1α and C-X-C chemokine receptor type 4.
Plus, the IV injection of MSC-h was able to diminish neuronal
death and inflammation in the cortex.
Even though these studies suggest hypoxia pre-conditioning
may improve MSC neuroprotective effect and increase MSC
survival after transplant, we found no studies that investigated
the potential use of this approach in the treatment of
neurodegenerative/polyQ disorders. Therefore, in the future
efforts should be made to better explore this strategy.
Pre-conditioning: Biomolecules/Chemicals
Pre-conditioning of MSC with biomolecules such as cytokines,
growth factors, or hormones can improve MSC survival
and efficiency. Indeed, Sadan and collaborators showed that
MSC that were pre-conditioned in media supplemented with
epidermal growth factor, human basic FGF, cyclic adenosine
monophosphate, human neuregulin1-β1, and platelet-derived
growth factor (Sadan et al., 2008, 2009) differentiated into
NTF secreting cells (NTF+) cells, which could secrete high
levels of BDNF and glial cell line-derived neurotrophic factor
(GDNF). NTF+ MSC could improve both the neuropathology
and behavior patterns in the QA rat model of HD (Sadan
et al., 2012). QA-injected rats transplanted with NTF+ MSC
lost less striatal volume than rats transplanted with naïve MSC.
Moreover, NTF+ MSC decreased T2 values when compared
with PBS-treated QA rats, as detected by MRI acquisitions.
Phenotypically, NTF+ cells were more efficient in reducing
rotational behavior than naïve MSC in QA-injected rats, thus
suggesting these cells to be more efficient.
In a recent study, the authors assessed the impact of culturing
MSC with different sera. MSC was cultured in medium with
10% of the following sera: fetal bovine serum, serum from
healthy controls (NS-MSC), or serum from stroke patients (SS-
MSC). Interestingly, SS-MSC had a higher proliferation rate
and lower senescence as well as increased expression of VEGF,
GDNF, and FGF. Additionally, SS-MSC promoted neurogenesis
and angiogenesis in stroke rat models, leading to improved
behavioral performance (Moon et al., 2018).
Alternatively, MSC can be primed using pharmacological
or chemical agents. Linares et al. (2016) investigated whether
pre-conditioning MSC with lithium and valproic acid (VPA)
could enhance their therapeutic effect. Lithium and VPA are
mood stabilizers known to exert neuroprotective effects (Chiu
et al., 2013) and pre-conditioning of MSC with these factors
led to an increase in the expression of genes involved in
trophic effects, as well as in pro-survival and immunomodulatory
pathways. Accordingly, N171–82Q transgenic HD mice were
treated with an intranasal administration of MSC or MSC
pre-conditioned with Lithium and VPA. The transplanted cells
migrated into the brain, with pre-conditioned MSC surviving for
a longer period. Moreover, mice treated with pre-conditioned
MSC showed a greater amelioration of motor and behavior
performance, decreased neuronal death, and reduction of
huntingtin aggregates in the striatum (Linares et al., 2016). This
strategy could be used in other polyQ diseases where Lithium and
VPA showed promising results (Saute et al., 2014; Esteves et al.,
2015; Lei et al., 2016; Lopes-Ramos et al., 2016).
Therefore, though pre-conditioning needs to be further
explored, the results obtained so far seem promising, which
opens good prospects for the near future.
Combined Treatment With
Pharmacological Agents
A less common strategy recently evaluated involved the use
of pharmacological agents in combination with MSC to treat
polyQ disorders. Elbaz et al. (2019) showed that the combined
administration of Lercanidipine (LER), an antihypertensive drug,
and MSC boosted their therapeutic efficiency in a rat model
for HD. LER is a vasoselective dihydropyridine calcium channel
blocker that can modulate calcium levels and, therefore may
be able to influence the calcineurin (CaN)/nuclear factor of
activated T cells c4 (NFATc4) pathway, which is deregulated
in neurodegenerative disorders (Sompol and Norris, 2018).
Treatment with LER, BM-MSC, or a combination of LER and
BM-MSC was given to 3-NP rats. The combined treatment with
LER and BM-MSC had the most promising results by leading
to greater amelioration of motor and behavioral performance.
Moreover, the levels of BDNF, forkhead box P3, Wnt, and
β-catenin increased in the striatum, along with a decrease of
CaN, tumor necrosis factor-α, and NFATc4 protein expression
and the Bax/B-cell lymphoma 2. Their results suggest that
this combined therapy can promote neuroprotective effects by,
at least in part, suppressing Ca2+/CaN/NFATc4 and Wnt/β-
catenin signaling pathways activation, which is dysregulated in
the 3-NP rats as well as in other neurodegenerative disorders
(Sompol and Norris, 2018).
Hence, this study shows how a combination of factors can
produce a synergistic effect, so it would be interesting to further
investigate the neuroprotective potential of therapies combining
different drugs with MSC.
Genetically Engineered MSC
Another strategy that has been studied to enhance MSC’s
therapeutic efficiency is the production of genetically engineered
MSC that can be used as delivery vehicles (Park et al.,
2015). For the treatment of neurodegenerative diseases, the
most common approaches include the use of MSC that
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were either virally or non-virally modified to overexpress
trophic factors known to have neuroprotective actions
(Huang et al., 2012; Deng et al., 2016).
Concerning polyQ disorders, only two studies are available in
the literature. The safety and efficacy of genetically engineered
MSC have been tested in HD animal models. In 2010, BM-MSC
were genetically engineered to over-express BDNF (MSC-BDNF)
and/or NGF (MSC-NGF), thus allowing these cells to deliver
these factors in higher amounts than normal MSC (Dey et al.,
2010). YAC128 transgenic mice were treated with MSC-BDNF,
MSC-NGF, or with both MSC-BDNF and MSC-NGF. MSC
was administered through bilateral injections into the striatum.
From all the tested groups, YAC128 transgenic mice transplanted
with MSC-BDNF exhibited the best outcomes, showing the least
neuronal loss and the highest latencies to fall values in rotarod.
Another study demonstrated that human MSC modified
by lentiviral transduction to overexpress BDNF (MSC-BDNF)
could ameliorate HD symptoms in two different animal
models, YAC128 and R6/2 transgenic mice in a higher extent
(Pollock et al., 2016). The intrastriatal transplantation of
MSC-BDNF decreased striatal atrophy and reduced anxiety levels
in YAC128 mice. Additionally, MSC-BDNF administration
promoted neurogenesis-like activity and led to an increase in
mice lifespan. Notably, mice treated withMSC-BDNF had overall
better outcomes than those treated with non-modified MSC.
Despite the few studies using genetically engineered MSC to
treat polyQ disorders, this type of approach has been further
explored in other neurodegenerative diseases, namely in AD and
PD, also with promising results (Li et al., 2008; Moloney et al.,
2010; Ren et al., 2013; Hoban et al., 2015).
Importantly, since neurodegenerative disorders have
common pathogenic mechanisms, current evidence obtained
from these studies indicate that genetically modified MSC
to overexpress various trophic factors is strong therapeutic
candidates for several neurodegenerative diseases, including
polyQ disorders.
CELLULAR-FREE APPROACHES
The Success of Studies Using MSC’s
Secretome in PolyQ/Other
Neurodegenerative Disorders
Several studies detected reduced numbers of MSCs in the
targeting tissues suggesting that MSCs can also act through
paracrine mechanisms. Conditioned medium (CM) of
MSC (CM-MSC), i.e., MSC’s secretome, can reproduce the
therapeutic effects obtained with MSC treatment in several
neurological diseases.
Bai et al. (2012) demonstrated that CM-MSC mitigates
functional abnormalities in a mouse model of multiple sclerosis
by promoting oligodendrocyte and neuron development. Suto
et al. (2016) showed that injections of MSC released factors,
such as HGF, improvedmotor coordination in an SCA-1-Knock-
in mouse model. Indeed, the administration of CM-MSC was
able to protect axons and myelin of spinal motor neurons
(Suto et al., 2016). Importantly, such improvements were
similar to those obtained in previous work using the same
model of disease in which animals were treated with MSC
(Mieda et al., 2016).
An antibody-based protein array analysis and ELISA showed
that, in addition to HGF, IGF-1, VEGF, and transforming
growth factor (TGF)-β-1 are present in the CM. However, the
combination of these factors is not as effective as treatment
with CM in promoting neuronal survival and neurite outgrowth,
which suggests that CM contains other complementary key
factors (Nakano et al., 2010). The secretion of BDNF and NGF
by MSC has also been demonstrated to promote neuronal/glial
survival and neurogenesis (Crigler et al., 2006). Likewise, the
beneficial effect of MSC may also be mediated by secretion of
GDNF, basic FGF-2, CNTF, angiopoietin-1, and neurotrophin-3
(Chen et al., 2005; Onda et al., 2008). Besides, the extracellular
matrix proteins, including collagen, fibronectin, and laminin
(Hidalgo-Bastida and Cartmell, 2010) provide physical guidance,
support neurogenesis, and may exert trophic activity themselves
(Maltman et al., 2011).
Recently, Ebrahimi et al. (2018) demonstrated that CM
collected from UC-MSC protect PC12 cells against superoxide-
induced oxidative stress, increasing cell viability, and neurite
outgrowth. GDNF and VEGF were detected in CM of UC-MSC
and were linked to the neuroprotective effects observed.
Moreover, it has been demonstrated that both human
adipose-derived MSC and their CM could reduce neuronal cell
damage in a model of glutamate excitotoxicity, a mechanism
that plays a role in the pathogenesis of neurodegenerative
diseases. Indeed, co-cultures with MSC using a transwell system
or addition of CM similarly promoted axonal regeneration,
energy metabolism improvements, and prevented apoptosis
of cortical neurons (Hao et al., 2014). In another study,
Miranda et al. (2011) showed that in a transwell system that
immortalized BM-MSC could stimulate neurite outgrowth in a
neurotrophin-dependent manner including BDNF secretion in
Twitcher-derived DRG neurons, an in vitro model of Krabbe’s
disease. Moreover, the administration of exogenous BDNF to
the sciatic nerve of Twitcher mice through BDNF-delivering
osmotic pumps promoted morphometric ameliorations,
suggesting BDNF as a promising candidate to be used in
combination with BM-MSC treatment (Miranda et al., 2011).
Nevertheless, simultaneous transplantation of BM-MSC and
treatment with an antagonist of TrK receptors in a model of
sciatic nerve crush completely reversed the inhibitory effect
of the antagonist, suggesting that other mechanisms may
be compensating the action of neurotrophins blocked by
the antagonist.
A recent study has shown that CM-MSC promoted
neuroprotective activities in in vitro PD models by increasing
the viability of both rat and human dopaminergic neurons
exposed to a neurotoxic insult (Parga et al., 2018). Additionally,
the administration of MSC secretome through an injection
into the substantia nigra and striatum in a PD mouse model
led to an increase of dopaminergic neurons and neuronal
terminals in those brain regions, which likely mediated the
observed temporary motor performance improvements. Also,
their findings suggest that the beneficial effects of human MSC
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secretome correlated with the increased presence of several
neuroregulatory molecules, such as GDNF, BDNF, interleukin-6
(IL-6), VEGF, pigment epithelium-derived factor (PEDF),
cystatin C, glia-derived nexin (GDN) and galectin-1 (Teixeira
et al., 2017).
Alternatively, MSC potent anti-inflammatory and
immunoregulatory effects might play a central role in tissue
regeneration. For instance, MSC are suggested to inhibit T
and B cell proliferation (Di Nicola et al., 2002; Franquesa
et al., 2012), natural killer cytotoxicity (Spaggiari et al., 2008),
and monocyte differentiation and maturation into dendritic
cells (Ivanova-Todorova et al., 2009). These capacities have
been linked to the release of molecules like indoleamine 2,3-
dioxygenase (IDO), prostaglandin E2, interleukin-10 (IL-10),
human leukocyte antigen-G, TGF-β, and HGF (Dorronsoro
et al., 2013). It has been demonstrated that the systemic
administration of CM derived from amniotic membrane MSC
ameliorates motor dysfunctions, brain pathology, and decreased
microglial activation in HD animal model (Giampà et al., 2019).
In summary, the bioactive molecules released by MSC
can exert angiogenic, immunomodulatory, neurogenic,
neuroprotective, and anti-apoptotic effects. Therefore,
MSC’s secretome seems to improve symptoms of several
neurodegenerative disorders, including polyQs, in a paracrine-
mediated manner, representing an alternative to cell therapies.
Extracellular Vesicles: Important Mediators
of MSC Communication With Host Cells
and Their Environment
MSC are known to release EVs, a group of heterogeneous
membrane-limited structures secreted by almost all cell types.
Exosomes are the most studied subpopulation of EVs that can
are divided by intracellular origin, size, and cargo. EVs are
recognized as important mediators of intercellular cross-talk
communication, being involved in both physiological and
pathological processes (Thery et al., 2002; Zöller, 2009; Colombo
et al., 2014). In fact, after being released into the extracellular
space, EVs can be internalized by recipient cells and transfer their
content. Then, their cargo may either be degraded or mediate
various signaling functions, modifying cellular fate, function,
and/or plasticity (Figure 3; Mulcahy et al., 2014; Abels and
Breakefield, 2016).
Depending on their subpopulation, the cell type of origin,
and specific environmental challenges (for example stress
conditions), EVs biomolecular content will change, bearing
different lipids, proteins, and nucleic acids. To standardize
the field, MISEV guidelines were created by the International
Society of Extracellular vesicles (ISEV; Thery et al., 2018).
Moreover, a harmonization criterion for MSC-EVs was created
by four societies, ISEV, Society for Clinical Research and
Translation of Extracellular Vesicles Singapore (SOCRATES),
International Society for Cell and Gene Therapy (ISCT), and
International Society of Blood Transfusion (ISBT), to boost
MSC-EVs applications in clinical settings (Witwer et al., 2019).
Given EVs’ physiological importance and role in brain
disorders, their potential therapeutic use has been explored over
the last decades. A comprehensive review can be found in Rufino-
Ramos et al. (2017).
EVs Derived From MSC
The general morphological characteristics of EVs derived from
MSC are common with EVs from other sources, yet they possess
some distinctive features. Besides common surface markers, like
CD9, CD63, and CD81, MSC-derived EVs also possess specific
MSC integrins and adhesive molecules, including CD29, CD44,
CD90, and CD73 (Lai et al., 2012). Their combination defines
tropism to specific tissues.
EVs derived from MSC encapsulate mRNAs, miRNAs, and
proteins related tomultiple signaling pathways, namely cell cycle,
proliferation, differentiation, and self-renewal (Lai et al., 2010;
Kim et al., 2012). However, as aforementioned, extracellular
conditions can affect their composition (Xin et al., 2014). Indeed,
Lai et al. (2012) demonstrated that MSC-derived EVs obtained
from CM from three different batches of the same cells had only
154 proteins in common. Furthermore, pre-conditioning MSC
with other cells and/or exposure to disease insults may change
exosomes’ secretion profile (Kim et al., 2007; Sano et al., 2014;
Cui et al., 2018).
Over the last decade, EVs derived from MSC have become
promising therapeutic tools as researchers hypothesized that
they may be the main paracrine effectors of MSC. In 2010,
the therapeutic potential of MSC-derived EVs was tested in a
mouse model of ischemia (Lai et al., 2010). Since then, EVs
have been investigated in several other disease models, such
as cardiovascular disorders (Wang N. et al., 2017), kidney
injury (Aghajani Nargesi et al., 2017; Farzamfar et al., 2019),
immune diseases (Lai et al., 2018, 2019), tumor growth (Wu
et al., 2013; Zhang et al., 2017) and neurological diseases (Wang
et al., 2018; Gorabi et al., 2019), obtaining encouraging results
(Yu et al., 2014).
MSC-EVs have been shown to exert similar functions to
those of the progenitor cells, participating in tissue repair and
regeneration, immune system modulation, and inflammatory
suppression in neurodegenerative disorders (Pashoutan Sarvar
et al., 2016). Xin et al. (2013) performed a proof-of-concept
study providing evidence that treatment with MSC-derived EVs
alone could promote functional recovery, neurogenesis, and
neurovascular remodeling in rats subjected to middle cerebral
artery occlusion, a stroke model. Interestingly, the outcomes
were similar to those obtained with systemic administration
of MSC. In a previous study, the same group had found that
MSC was able to promote neurite outgrowth and functional
recovery partially by the transference of miRNA 133b (miR-
133b) via exosomes (Xin et al., 2012). Levels of miR-133b were
increased in the ipsilateral hemisphere of the stroke rat model
after treatment with MSC. Plus, in vitro exposure of MSC to
damaged brain tissue led to the enrichment of miR-133b in cells
and their exosomes. Finally, when primary neurons co-cultured
with astrocytes were treated with these exosomes, miR-133b
levels were found to be increased. Moreover, this effect was
lost in astrocytes treated with a miR-133b inhibitor. In this
way, Xin et al. (2012) showed that exosomes play a role in
MSC communication with brain parenchymal cells, mediating
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the transfer of bioactive molecules like miR-133b. In a different
context, EVs isolated from adipose-derived stromal cells (AD-
MSC) exerted a neuroprotective effect in an in vitro model of
amyotrophic lateral sclerosis (ALS). Upon an oxidative insult, the
motoneuron-like NSC-34 cells expressing ALS mutations were
treated with exosomes, which showed the capacity to protect
ALSmotoneurons from oxidative stress, increasing their viability
(Bonafede et al., 2016).
In line with those results, in another study, it was
demonstrated that both MSC and MSC-derived EVs were able
to protect hippocampal neurons from oxidative stress and
synapse damage induced by amyloid-β peptide (AβO) upon IC
delivery (de Godoy et al., 2018). These authors also unveiled
that such neuroprotective action could be explained by MSC’s
ability to internalize and degrade AβO, secret EVs, as well as
trophic and anti-inflammatory cytokines. EVs were shown to
contain an antioxidant enzyme, catalase, which contributed to
the decrease of oxidative stress. Recently, Reza-Zaldivar et al.
(2019) also reported that both MSC and MSC-derived EVs were
similarly able to promote neurogenesis and ameliorate cognitive
impairments caused by β amyloid 1–42 aggregates, an established
Alzheimer’s disease animal model.
Hypoxia conditions were shown to increase mir-21 levels in
MSC cells and their derived EVs. By systemically injecting EVs
in Transgenic APP/PS1, it has been shown that EVs produced
during hypoxia could reach the brain and increase the levels of
mir-21. By increasing the levels of mir-21 in the brain, learning
and memory capabilities were restored while plaque deposition
and Aβ levels were decreased. These findings substantiate the
therapeutic potential of MSC-EVs in Alzheimer’s disease context
(Cui et al., 2018).
MSC can ultimately be genetically modified to enhance EVs
production that specifically targets the brain and promote cargo
delivery in neurons. Kojima et al. (2018) engineered MSC to:
(1) boost EVs production by acting in exosomes biogenesis;
(2) package mRNA catalase inside EVs; and (3) express at EVs
surface the RVG peptide that targets the brain and connexin 43 to
enhance information transference in the target cells. This study
showed that engineered cells can produce modified EVs able to
deliver therapeutic cargo to the brain in a PD model (Kojima
et al., 2018).
One of the major drawbacks of using MSC-EVs for
brain therapy is the low number of vesicles that cross BBB
and reach the brain. To overcome this, a recent study
engineered MSC derived vesicles with magnetic properties
that reach the brain after application of a magnetic field
(Kim et al., 2020). Moreover, stimuli with magnetic particles
increase growth factors expression in MSC-derived vesicles.
These magnetic vesicles were administered through a systemic
injection in middle-cerebral-artery-occlusion (MCAO)-induced
rats promoting anti-inflammatory response, angiogenesis, and
anti-apoptosis in the ischemic brain lesion leading to an
improvement in the motor function.
Altogether, these studies support the idea that EVs derived
from MSC may be an important player in the paracrine effect
of MSC and, therefore, a potential therapeutic agent for the
treatment of polyQ diseases.
HOW TO STANDARDIZE MSC OR MSC’s
EFFECTORS?
As aforementioned, multiple extrinsic factors including
tissue source, culture methods, passage number, and oxygen
concentration can significantly interfere with MSC innate
functional potential (Hagmann et al., 2013; Lee et al., 2013;
Heathman et al., 2015; Elahi et al., 2016). To comply with
Good Manufacturing Practices (GMP) and current Good Tissue
Practices, certain aspects of MSC or MSC’s effector’s production
like: (1) the method of isolation; (2) culture medium, serum and
supplements used; (3) cell seeding density; and (4) devices of
expansion, must be optimized and standardized, thus ensuring
consistent production, efficacy, and safety (Rojewski et al., 2013;
Sensebé et al., 2013; Sharma et al., 2014).
Another important aspect that needs further clarification is
the cryopreservation procedure as no consensus on whether
the use of freshly cultured or freeze-thawed MSC is more
advantageous. Multiple studies are showing that thawed
MSC/MSC products have reduced therapeutic capabilities
(François et al., 2012; Chinnadurai et al., 2016, 2018) and,
contrarily, some studies demonstrate that both thawed and fresh
MSC have similar functionalities (Cruz et al., 2015; Bárcia et al.,
2017; Tan et al., 2019). One explanation for this disparity may
be the temperature fluctuation under frozen conditions (Chabot
et al., 2017).
Given the heterogeneity of practices and outcomes among
different laboratories, both in pre-clinic and clinic grades, in
2016 ISCT issued a position statement urging the need to
identify MSC functional markers of potency and implement
assays for the measurement of such markers. This is a
fundamental step that could help in predicting and improving the
efficiency of MSC related therapies, meeting the requirements of
Regulatory Authorities for extensive quality-control protocols for
advanced clinical studies and registrations (Galipeau et al., 2016).
Nevertheless, MSC has complex mechanisms of action that are
not yet completely understood, which hinders the determination
of which biological proprieties of MSC are more relevant
to assess (Galipeau and Krampera, 2015). Ideally, multiple
complementary assays (matrix assay) should be developed to
characterize several attributes of MSC/MSC’s effectors that may
be important for each therapeutic purpose (Galipeau et al., 2016).
Regarding studies that use MSC/MSC’s effectors as a
therapeutic agent for neurodegenerative disorders, in addition
to current characterization criteria, which include the presence
and/or absence of specific markers and their differentiation
potency (Dominici et al., 2006), it is essential to establish assays
for the analysis of their immunomodulatory capability and
senescence status, especially in clinical settings. A summary of the
assays that could be used to standardize MSC/MSC’s effectors is
given in Table 4.
It has been demonstrated that after multiple passages, MSC
enters senescence, and cells show loss of differentiation potential,
different secretion profiles, and telomere shortening (Wagner
et al., 2008). Thus, sensitive evaluation of key genes and/or
molecules involved in senescence pathways such as myc, p21,
Frontiers in Cellular Neuroscience | www.frontiersin.org 18 October 2020 | Volume 14 | Article 584277






















































































































































































































































































































































































































































































































































































































































































































































































































































































p53, p16ink4, hTERT is essential to guarantee the genomic
stability of MSC in long-term culture (Tarte et al., 2010).
In 2018, Chinnadurai et al. (2018) proposed for the first
time a dual assay matrix approach that combined secretome
analysis and quantitative RNA-based array to characterize
MSC crosstalk interaction with peripheral blood mononuclear
cells (PBMC) upon co-culture. In this study the authors
identified cytokines and chemokines whose increased or
decreased expression directly correlated with MSC ability to
suppress PMBC proliferation, reporting on MSC functionality
to modulate the secretome immune response (Chinnadurai
et al., 2018). Recently, the same group developed another
assay matrix approach based on the phosphorylation of signal
transducer and activator of transcription (STAT) of MSC after
interaction withMSC-PBMC co-culture secretome. This informs
on MSC functionality to sense and modulate the environment.
The authors reported that STAT1 and STAT3 phosphorylation
correlated with MSC immunoinhibitory ability (Chinnadurai
et al., 2019). Nevertheless, depending on the disease, instead of
PBMCs, the use of immune effector cells directly involved in
the pathogenic mechanisms of the diseases may be more suitable
and preferable.
Furthermore, Boregowda et al. (2016) developed a Clinical
Indications Prediction (CLIP) scale for different diseases
that predicts the therapeutic efficacy of populations of MSC
from different donors, based on the expression levels of
the transfection factor TWIST1. MSC expressing high levels
of TWIST1 have greater angiogenic potential whereas low
TWIST1 expressing populations are predicted to have higher
anti-inflammatory and immunomodulatory capabilities.
Nonetheless, these potency assays still bear limitations, not
providing complete predictive guidance. To complement these
strategies in the future, it would also be important to study
patient clinical parameters, such as the stage of the disease, co-
morbidities, and age, among others, which could help predict
patient responsiveness to treatment. Additionally, donors’ age,
gender, and clinical status should also be carefully considered. As
different studies offer contradictory information on the impact
of such parameters (Stolzing et al., 2008; Andrzejewska et al.,
2019), a greater understanding of how these characteristics may
correlate with MSC proliferation, multipotency, and efficiency
is needed.
We expect that further research may shed light on
MSC heterogeneity and their highly complex mechanisms of
action, thus facilitating the optimization and standardization
of MSC/MSC effector processes, leading to higher quality-
control protocols along with better and more consistent
therapeutic outcomes.
CONCLUSION: MSC—DO THEY HAVE A
FUTURE IN PolyQ CLINICAL THERAPIES?
MSC have gathered considerable interest among the scientific
community and their application to neurodegenerative disorders
has not been an exception. It has been reported that the
therapeutic application of MSC can produce encouraging results
as they can promote tissue regeneration and cell turnover
Frontiers in Cellular Neuroscience | www.frontiersin.org 19 October 2020 | Volume 14 | Article 584277
Barros et al. MSC for PolyQ Disorders
by: (i) increasing cell survival; (ii) inducing neurogenesis;
(iii) inhibiting apoptosis; and (iv) modulating inflammation,
among others, mainly through paracrine mechanisms. Further
supporting their therapeutic potential, clinical trials have
demonstrated that MSC are safe and may produce beneficial
results in different neurodegenerative disorders. In polyQ
disorders, patients enrolled in clinical trials showed a delay in
the progression of disease symptoms. However, a considerable
percentage of patients were reported to regress to their
status before transplantation, indicating that MSC beneficial
effects must be transient. On the other hand, the lack of
appropriate animal models that could better mimic these
human diseases is another limiting issue, as this hardens
result interpretation.
Meanwhile, several strategies have emerged that aim at
increasing either MSC survival or their efficacy in vivo.
Pre-conditioning with hypoxic conditions or biomolecules, a
combination of MSC with other pharmacological agents, or
genetic modification of cells are some of these possible strategies.
On the other hand, due to the strong paracrine properties of
MSC, cell-free approaches usingMSC secretome orMSC-derived
EVs have naturally become a motif of interest in the case of
neurological disorders, as they take advantages of the paracrine
neuroprotective effect of MSC. Finally, it would be important
to not only standardize procedures regarding MSC-derived
therapies but also to uncover the role that MSC exert in polyQ
models. Pinpointing possible MSC effects will certainly open
avenues for triggering novel therapeutic targets for this group of
neurodegenerative disorders.
As a conclusion, the final goal may now be to implement
more standardized studies to discover a promising cell or
cell-free based therapeutic strategy amenable to systemic delivery
and enabling stably reaching the brain. In our point of view,
this strategy would mean an add-on value in the clinics as
it can be easily implemented due to its safety and minimally
invasive character.
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